Shahram Bahmanyar

Shahram Bahmanyar

Auto-generated profile, based on publicly available information

Shahram Bahmanyar

Clinical Epidemiology Unit & Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2012 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
RNRichard Nordenvall
Richard Nordenvall
SBShahram Bahmanyar
Shahram Bahmanyar
JAJohanna Adami
Johanna Adami
CSCarin Stenros
Carin Stenros
TWTorsten Wredmark
Torsten Wredmark
LFLi Felländer-Tsai
Li Felländer-Tsai
Background: A few national cruciate ligament (CL) registers have been initiated with operative surveillance and outcome monitoring. No nationwide study describing CL injury has ever been done. Purpose: To study the incidence and characteristics of patients diagnosed with cruciate ligament injury in Sweden. Study Design: Descriptive epidemiology study. Methods: Data for all patients with a diagnosed CL injury between 2001 and 2009 were identified from the National Swedish Patient Register. Risk analysis and specific incidences were calculated according to age, sex, geographic region, and surgery. Results: A total number of 56,659 patients with CL injury were included in the study, and the overall incidence of CL injury in Sweden was 78 per 100,000 persons. Sixty percent of the patients were male. The mean age was 32 years (range, 1-98 years), and 50% of the cohort was younger than 30 years. There was an increased rate of injury among female patients younger than 20 years as compared with male patients in that age group. Among patients with CL injury, 36% underwent reconstructive surgery, with one-third of these performed within 1 year after injury. Among patients who underwent surgery, 59% were male; the mean age was 27 years (range, 5-89 years). Conclusion: This study defines the incidence of CL injury and also demonstrates sex differences in which men were more likely to sustain a CL injury, although female patients were injured at an earlier age. The findings in this study corroborate the results from recent surgical registers. Clinical Relevance: No data have hitherto been published including all patients with CL injury, treated both surgically and nonsurgically. Such baseline epidemiologic data are crucial to be able to validate and judge the generalizability of results from procedure registers and clinical studies.

1 August 2008 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
ABAnnika Bergquist
Annika Bergquist
SMScott M. Montgomery
Scott M. Montgomery
SBShahram Bahmanyar
Shahram Bahmanyar
RORolf Olsson
Rolf Olsson
ÅDÅke Danielsson
Åke Danielsson
AEAnders Ekbom
Anders Ekbom

31 March 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
SBS. Bahmanyar
S. Bahmanyar
SMS. M. Montgomery
S. M. Montgomery
JHJ. Hillert
J. Hillert
AEA. Ekbom
A. Ekbom
TOT. Olsson
T. Olsson
Background: We investigated cancer risk among patients with multiple sclerosis (MS) and whether variation by age at MS diagnosis helps to elucidate mechanisms underlying the previously reported reduced cancer risk. We also studied cancer risk among parents to ascertain if MS susceptibility genes may confer protection against cancer in relatives.

28 December 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
LPLaura Pazzagli
Laura Pazzagli
MLMarie Linder
Marie Linder
MZMingliang Zhang
Mingliang Zhang
EVEmese Vago
Emese Vago
PSPaul Stang
Paul Stang
SBShahram Bahmanyar
Shahram Bahmanyar
Purpose: Lack of control for time‐varying exposures can lead to substantial bias in estimates of treatment effects. The aim of this study is to provide an overview and guidance on some of the available methodologies used to address problems related to time‐varying exposure and confounding in pharmacoepidemiology and other observational studies. The methods are explored from a conceptual rather than an analytical perspective.Methods: The methods described in this study have been identified exploring the literature concerning to the time‐varying exposure concept and basing the search on four fundamental pharmacoepidemiological problems, construction of treatment episodes, time‐varying confounders, cumulative exposure and latency, and treatment switching.Results: A correct treatment episodes construction is fundamental to avoid bias in treatment effect estimates. Several methods exist to address time‐varying covariates, but the complexity of the most advanced approaches—eg, marginal structural models or structural nested failure time models—and the lack of user‐friendly statistical packages have prevented broader adoption of these methods. Consequently, simpler methods are most commonly used, including, for example, methods without any adjustment strategy and models with time‐varying covariates. The magnitude of exposure needs to be considered and properly modelled.Conclusions: Further research on the application and implementation of the most complex methods is needed. Because different methods can lead to substantial differences in the treatment effect estimates, the application of several methods and comparison of the results is recommended. Treatment episodes estimation and exposure quantification are key parts in the estimation of treatment effects or associations of interest.

16 March 2013 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SMS. Montgomery
S. Montgomery
JHJ. Hillert
J. Hillert
SBS. Bahmanyar
S. Bahmanyar

18 December 2017 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
APAnton Pottegård
Anton Pottegård
SFSøren Friis
Søren Friis
TSTil Stürmer
Til Stürmer
JHJesper Hallas
Jesper Hallas
SBShahram Bahmanyar
Shahram Bahmanyar
In this MiniReview, we provide general considerations for the planning and conduct of pharmacoepidemiological studies of associations between drug use and cancer development. We address data sources, study design, assessment of drug exposure, ascertainment of cancer outcomes, confounder adjustment and future perspectives. Aspects of data sources include assessment of complete history of drug use and data on dose and duration of drug use, allowing estimates of cumulative exposure. Outcome data from formal cancer registries are preferable, but cancer data from other sources, for example, patient or pathology registries, medical records or claims are also suitable. The two principal designs for observational studies evaluating drug–cancer associations are the cohort and case–control designs. A key challenge in studies of drug–cancer associations is the exposure assessment due to the typically long period of cancer development. We present methods to examine early and late effects of drug use on cancer development and discuss the need for employing ‘lag‐time’ in order to avoid reverse causation. We emphasize that a new‐user study design should always be considered. We also underline the need for ‘dose–response’ analyses, as drug–cancer associations are likely to be dose‐dependent. Generally, studies of drug–cancer associations should explore risk of site‐specific cancer, rather than cancer overall. Additional differentiation may also be crucial for organ‐specific cancer with various distinct histological subtypes (e.g., lung or ovary cancer). We also highlight the influence of confounding factors and discuss various methods to address confounding, while emphasizing that the choices of methods depend on the design and specific objectives of the individual study. In some studies, use of active comparator(s) may be preferable. Pharmacoepidemiological studies of drug–cancer associations are expected to evolve considerably in the coming years, due to the increasing availability of long‐term data on drug exposures and cancer outcomes, the increasing conduct of multinational studies, allowing studies of rare cancers and subtypes of cancer, and methodological improvements specifically addressing cancer and other long‐term outcomes.